Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis (1989)

Posted on by WOCredentials

“as THC has been shown to inhibit both clinical and histologic [experimental autoimmune encephalomyelitis], it may prove to be a new and relatively innocuous agent for the treatment of immune-mediated diseases.”

Lyman, W. D., Sonett, J. R., Brosnan, C. F., Elkin, R., & Bornstein, M. B. (1989). Δ9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 23(1), 73-81. DOI: 10.1016/0165-5728(89)90075-1

Read more…

Discover more from ContraReport

Subscribe to get the latest posts sent to your email.

Related Posts

Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype (2013)

“Here we show that the main psychoactive cannabinoid, Δ-9-tetrahydrocannabinol (THC), and the main nonpsychoactive cannabinoid, cannabidiol (CBD), markedly reduce the Th17 phenotype which is known to be increased in inflammatory […]

Cannabinoids remove plaque-forming Alzheimer’s proteins

“Salk Institute scientists have found preliminary evidence that tetrahydrocannabinol (THC) and other compounds found in marijuana can promote the cellular removal of amyloid beta, a toxic protein associated with Alzheimer’s […]

One striking chart shows why pharma companies are fighting legal marijuana

“Our findings and existing clinical literature imply that patients respond to medical marijuana legislation as if there are clinical benefits to the drug, which adds to the growing body of […]